- Home
- EIC vs LUNG Comparison
EIC vs LUNG Comparison
Compare EIC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- LUNG
- Stock Information
- Founded
- EIC N/A
- LUNG 1995
- Country
- EIC United States
- LUNG United States
- Employees
- EIC N/A
- LUNG N/A
- Industry
- EIC Finance/Investors Services
- LUNG Industrial Specialties
- Sector
- EIC Finance
- LUNG Health Care
- Exchange
- EIC Nasdaq
- LUNG Nasdaq
- Market Cap
- EIC 349.4M
- LUNG 124.0M
- IPO Year
- EIC 2019
- LUNG 2020
- Fundamental
- Price
- EIC $13.78
- LUNG $2.87
- Analyst Decision
- EIC Strong Buy
- LUNG Buy
- Analyst Count
- EIC 1
- LUNG 6
- Target Price
- EIC $17.50
- LUNG $11.53
- AVG Volume (30 Days)
- EIC 204.2K
- LUNG 317.8K
- Earning Date
- EIC 08-05-2025
- LUNG 07-30-2025
- Dividend Yield
- EIC 17.48%
- LUNG N/A
- EPS Growth
- EIC N/A
- LUNG N/A
- EPS
- EIC 0.55
- LUNG N/A
- Revenue
- EIC $51,224,692.00
- LUNG $87,473,000.00
- Revenue This Year
- EIC $42.67
- LUNG $18.02
- Revenue Next Year
- EIC $29.16
- LUNG $18.17
- P/E Ratio
- EIC $24.89
- LUNG N/A
- Revenue Growth
- EIC 68.61
- LUNG 19.84
- 52 Week Low
- EIC $12.63
- LUNG $2.50
- 52 Week High
- EIC $16.71
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- EIC 59.85
- LUNG 39.07
- Support Level
- EIC $13.64
- LUNG $2.62
- Resistance Level
- EIC $13.92
- LUNG $2.88
- Average True Range (ATR)
- EIC 0.16
- LUNG 0.17
- MACD
- EIC 0.07
- LUNG 0.05
- Stochastic Oscillator
- EIC 96.83
- LUNG 39.68
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.